keyword
MENU ▼
Read by QxMD icon Read
search

IL-31

keyword
https://www.readbyqxmd.com/read/28906040/a-blinded-randomized-clinical-trial-evaluating-the-efficacy-and-safety-of-lokivetmab-compared-to-ciclosporin-in-client-owned-dogs-with-atopic-dermatitis
#1
Hilde Moyaert, Leen Van Brussel, Stasia Borowski, Monica Escalada, Sean P Mahabir, Rodney R Walters, Michael R Stegemann
BACKGROUND: Lokivetmab is an injectable anti-canine-IL-31 monoclonal antibody to treat clinical manifestations of atopic dermatitis (AD) in dogs. HYPOTHESIS/OBJECTIVES: To characterize the efficacy and safety of lokivetmab, and to demonstrate its noninferiority to ciclosporin under field conditions. ANIMALS: Dogs with chronic AD (n = 274) were enrolled from 40 practices in Belgium, The Netherlands, France and Germany. METHODS: Animals were randomized (1:1) to oral ciclosporin (5 mg/kg/once daily) or monthly injectable lokivetmab (1-3...
September 14, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28887947/therapeutic-pipeline-for-atopic-dermatitis-end-of-the-drought
#2
REVIEW
Amy S Paller, Kenji Kabashima, Thomas Bieber
Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants. The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation. Most agents are in phase 2 clinical trials. Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available in late 2016 in the United States for mild-to-moderate AD, with other PDE4 inhibitors, an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in trials for topical application...
September 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28887844/house-dust-mite-allergens-der-f-and-der-p-induce-il-31-production-by-blood-derived-t-cells-from-atopic-dermatitis-patients
#3
Krisztina Szegedi, Amanda van Lier, Pieter C Res, Saskia Chielie, Jan D Bos, Sanja Kezic, Maritza A Middelkamp-Hup, Rosalie M Luiten
No abstract text is available yet for this article.
September 8, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28861617/novel-therapeutic-approaches-to-atopic-dermatitis
#4
REVIEW
Katarzyna Osinka, Karolina Dumycz, Bartłomiej Kwiek, Wojciech Feleszko
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. The number of people affected by AD is relatively high and seems to be rising. Although mild and moderate forms of the disease can be well controlled by the use of emollients, topical corticosteroids, and topical calcineurin inhibitors, treatment of severe is still a huge challenge. The new hope is biologic drugs, magic bullets in allergy, targeted at different points of the complex pathomechanism of inflammation in AD. In this review, novel biologic therapies are discussed, including recombinant monoclonal antibodies directed against various interleukin pathways (such as IL-4, IL-13, TSLP, IL-31, and IL-12/23), on immunoglobulin E, molecules acting as T cells, B cells, etc...
August 31, 2017: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/28853956/new-and-emerging-targeted-systemic-therapies-a-new-era-for-atopic-dermatitis
#5
Dylan E Lee, Ashley K Clark, Khiem A Tran, Vivian Y Shi
PURPOSE: This is a review of emerging targeted, systemic therapies for atopic dermatitis (AD). The information presented aims to provide dermatologists with updated therapeutic options, stimulate academic interest, and spark future research. MATERIALS AND METHODS: Extensive search of ClinicalTrials.gov, the National Eczema Association, and PubMed was performed for clinical trials examining the effect of emerging targeted, systemic therapies in patients with AD. Results were included if they demonstrated efficacy in reversing AD symptoms...
August 30, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28808661/the-role-of-intereukin-31-in-pathogenesis-of-itch-and-its-intensity-in-a-course-of-bullous-pemphigoid-and-dermatitis-herpetiformis
#6
Lilianna Kulczycka-Siennicka, Anna Cynkier, Elżbieta Waszczykowska, Anna Woźniacka, Agnieszka Żebrowska
Itch which is one of the major, subjective symptoms in a course of bullous pemphigoid and dermatitis herpetiformis makes those two diseases totally different than other autoimmune blistering diseases. Its pathogenesis is still not fully known. The aim of this research was to assess the role of IL-31 in development of itch as well as to measure its intensity. Obtained results, as well as literature data, show that lower concentration of IL-31 in patients' serum may be correlated with its role in JAK/STAT signaling pathway which is involved in development of autoimmune blistering disease...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28782487/natalizumab-changes-the-peripheral-profile-of-the-th17-panel-in-ms-patients-new-mechanisms-of-action
#7
Rodica Ioana Bălașa, Simu Mihaela, Septimiu Voidăzan, Laura Iulia Bărcuțean, Zoltan Bajko, Adina Huțanu, Iunius Simu, Smaranda Maier
INTRODUCTION: Natalizumab (NAT) is an effective treatment for relapsing remitting multiple sclerosis (RRMS),as it makes the blood-brain-barrier impenetrable bybinding to the α4integrin subunit. The objectives of our study were to find new peripheral mechanisms of action of NAT and new biomarkers of treatment response. MATERIAL AND METHODS: We prospectively assessed the serum levels of 15 cytokines from the Th17 Cytokine Panelusing Bio-plex Pro Human in a group of 29 RRMS patients treated with NAT and 29 healthy subjects(HS) at inclusion and after 8 months of NAT treatment...
August 7, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28698528/inflammatory-and-noninflammatory-itch-implications-in-pathophysiology-directed-treatments
#8
REVIEW
Lai-San Wong, Tiffany Wu, Chih-Hung Lee
Itch is the main chief complaint in patients visiting dermatologic clinics and has the ability to deeply impair life quality. Itch results from activation of cutaneous nerve endings by noxious stimuli such as inflammatory mediators, neurotransmitters and neuropeptides, causing itch signal transduction from peripheral skin, through the spinal cord and thalamus, to the brain cortex. Primarily noninflammatory diseases, such as uremic pruritus, cause itch through certain pruritogens in the skin. In inflammatory skin diseases, atopic dermatitis (AD) is the prototypic disease causing intensive itch by aberrant skin inflammation and epidermal barrier disruption...
July 10, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28670717/emerging-role-of-interleukin-31-and-interleukin-31-receptor-in-pruritus-in-atopic-dermatitis
#9
REVIEW
Masutaka Furue, Kazuhiko Yamamura, Makiko Kido-Nakahara, Takeshi Nakahara, Yoshinori Fukui
Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH 2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH 2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD...
July 3, 2017: Allergy
https://www.readbyqxmd.com/read/28668242/cockroach-allergen-exposure-and-plasma-cytokines-among-children-in-a-tropical-environment
#10
Brock H Medsker, Erick Forno, Yueh-Ying Han, Edna Acosta-Pérez, Angel Colón-Semidey, Maria Alvarez, John F Alcorn, Glorisa J Canino, Juan C Celedón
BACKGROUND: Little is known about the effects of socioeconomic status or cockroach allergen on immune responses in school-age children, particularly in tropical environments. OBJECTIVE: To examine whether cockroach allergen and/or socioeconomic status is associated with plasma cytokine levels in Puerto Rican children. METHODS: This was a cross-sectional study of 532 children (6-14 years old) with (n = 272) and without (n = 260) asthma in San Juan (Puerto Rico)...
July 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28658541/the-interplay-between-genetic-and-environmental-factors-in-the-pathogenesis-of-atopic-dermatitis
#11
REVIEW
Atsushi Otsuka, Takashi Nomura, Pawinee Rerknimitr, Judith A Seidel, Tetsuya Honda, Kenji Kabashima
Atopic dermatitis (AD) is a chronic skin disorder characterized by pruritus and recurrent eczematous lesions that are accompanied by T-helper (Th)2-dominated inflammation. AD Etiology is not yet completely understood, but it is multifactorial. Moreover, the disease is characterized by complex interactions between genetic and environmental factors, such as skin barrier dysfunctions, allergy/immunity, and pruritus. For example, filaggrin is a key protein involved in skin barrier function. Th2 cells produce interleukin (IL)-31, which provokes pruritus, and other Th2 cytokines decrease filaggrin expression by keratinocytes...
July 2017: Immunological Reviews
https://www.readbyqxmd.com/read/28652155/advances-in-atopic-dermatitis-and-urticarial-in-2016
#12
REVIEW
Tetsuya Honda, Takashi Nomura, Kenji Kabashima
This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis with human samples revealed different immune profiles between childhood and adult AD. Phase III clinical trials of dupilumab, an anti-IL-4 receptor α antibody, in the treatment of AD have successfully finished, and dupilumab will appear in clinical practice as the first biologic for AD in 2017...
August 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28607076/functional-proteogenomics-reveals-biomarkers-and-therapeutic-targets-in-lymphomas
#13
Delphine C M Rolland, Venkatesha Basrur, Yoon-Kyung Jeon, Carla McNeil-Schwalm, Damian Fermin, Kevin P Conlon, Yeqiao Zhou, Samuel Y Ng, Chih-Chiang Tsou, Noah A Brown, Dafydd G Thomas, Nathanael G Bailey, Gilbert S Omenn, Alexey I Nesvizhskii, David E Root, David M Weinstock, Robert B Faryabi, Megan S Lim, Kojo S J Elenitoba-Johnson
Identification of biomarkers and therapeutic targets is a critical goal of precision medicine. N-glycoproteins are a particularly attractive class of proteins that constitute potential cancer biomarkers and therapeutic targets for small molecules, antibodies, and cellular therapies. Using mass spectrometry (MS), we generated a compendium of 1,091 N-glycoproteins (from 40 human primary lymphomas and cell lines). Hierarchical clustering revealed distinct subtype signatures that included several subtype-specific biomarkers...
June 20, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28572699/associations-between-interleukin-31-gene-polymorphisms-and-dilated-cardiomyopathy-in-a-chinese-population
#14
Huizi Song, Ying Peng, Bin Zhou, Nan Chen, Xiaochuan Xie, Qingyu Dou, Yue Zhong, Li Rao
To explore the role of Interkeulin-31 (IL-31) in dilated cardiomyopathy (DCM), in our study, two SNPs of IL-31, rs4758680 (C/A) and rs7977932 (C/G), were analyzed in 331 DCM patients and 493 controls in a Chinese Han population. The frequencies of C allele and CC genotype of rs4758680 were significantly increased in DCM patients (P = 0.005, P = 0.001, resp.). Compared to CC genotype of rs4758680, the A carriers (CA/AA genotypes) were the protect factors in DCM susceptibility while the frequencies of CA/AA genotypes were decreased in the dominant model for DCM group (P < 0...
2017: Disease Markers
https://www.readbyqxmd.com/read/28558009/association-between-aqueous-humor-and-vitreous-fluid-levels-of-th17-cell-related-cytokines-in-patients-with-proliferative-diabetic-retinopathy
#15
Masaru Takeuchi, Tomohito Sato, Yutaka Sakurai, Manzo Taguchi, Kozo Harimoto, Yoko Karasawa, Masataka Ito
Inflammation is known to be involved in the progression of diabetic retinopathy. We have recently reported that vitreous levels of IL-4, IL-17A, IL-22, IL-31, and TNFα are higher than the respective serum levels in proliferative diabetic retinopathy (PDR) patients, and that vitreous levels of these cytokines are higher in PDR than in other non-inflammatory vitreoretinal diseases or uveitis associated with sarcoidosis. In the present study, we investigated inflammatory cytokines including Th17 cell-related cytokines in aqueous humor samples obtained from eyes with PDR, and analyzed the association between the aqueous humor and vitreous fluid levels of individual cytokines...
2017: PloS One
https://www.readbyqxmd.com/read/28512667/involvement-of-leukotriene-b4-released-from-keratinocytes-in-itch-associated-response-to-intradermal-interleukin-31-in-mice
#16
Tsugunobu Andoh, Ayako Harada, Yasushi Kuraishi
A recent study suggests that interleukin-31 (IL-31) exerts its effect via indirect mechanisms rather than through direct stimulation of cutaneous nerves. However, the underlying peripheral mechanisms of IL-31-induced itch in the skin remain unclear. Therefore, the present study investigated the peripheral mechanisms underlying IL-31-induced itch in mice. IL-31-induced itch-related response was inhibited by anti-allergic drugs (tranilast and azelastine), but not by an H1 histamine receptor antagonist (terfenadine)...
August 31, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28428802/regulation-of-th2-responses-by-different-cell-types-expressing-the-interleukin-31-receptor
#17
Saburo Saito, Ayana Aoki, Iwao Arai, Shinya Takaishi, Haruyasu Ito, Nobutake Akiyama, Hiroshi Kiyonari
BACKGROUND: Interleukin-31 (IL-31) is a recently identified cytokine produced by Th2 cells that is involved in the development of atopic dermatitis-induced skin inflammation and pruritus. Its receptor, IL-31RA, is expressed by a number of cell types, including epithelial cells, eosinophils, and activated monocytes and macrophages. To date, however, the regulation of Th2 responses by distinct cell types and tissues expressing IL-31RA has not been well studied. METHODS: In this study, Cry j 2, one of the major allergens of Japanese cedar pollen, was administered to IL-31RA-deficient or wild-type (WT) mice via nasal or intraperitoneal injection for induction of specific Th2 responses...
2017: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/28408397/the-il-31-il-31-receptor-axis-general-features-and-role-in-tumor-microenvironment
#18
REVIEW
Elisa Ferretti, Anna Corcione, Vito Pistoia
IL-31 is a recently identified cytokine with a well-defined role in the pathogenesis of pruritus. IL-31, whose production is induced by IL-4 and IL-33, binds a heterodimeric receptor (R) composed of the exclusive IL-31RA chain and the shared oncostatin M R. Signaling through the IL-31R involves the MAPK, PI3K/AKT and Jak/STAT pathways. Different variants and isoforms of IL-31RA with different signaling activities have been identified. IL-31 is produced predominantly by circulating Th2 lymphocytes and skin-homing CLA(+)CD45RO(+) T cells...
April 13, 2017: Journal of Leukocyte Biology
https://www.readbyqxmd.com/read/28303765/the-significance-of-the-levels-of-il-4-il-31-and-tlsp-in-patients-with-asthma-and-or-rhinitis
#19
Ruonan Chai, Beixing Liu, Feifei Qi
AIM: To investigate the clinical significance of the levels of IL-4, IL-33 and thymic stromal lymphopoietin (TLSP) in patients with asthma and/or rhinitis, then do the simple verification in animals. METHODS: Levels of IL-4 IL-31, IL-33 and TLSP were detected by ELISA and real-time PCR in 64 asthma patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases), 64 rhinitis patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases), 64 asthma complicated with allergic rhinitis patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases) and 32 healthy controls...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28265480/proximity-to-a-major-road-and-plasma-cytokines-in-school-aged-children
#20
Franziska Rosser, Erick Forno, John Brehm, Yueh-Ying Han, Nadia Boutaoui, Angel Colón-Semidey, María Alvarez, Edna Acosta-Pérez, Kristen S Kurland, John F Alcorn, Glorisa Canino, Juan C Celedón
Traffic-related air pollution (TRAP) may affect immune responses, including those in the TH2 and TH17 pathways. To examine whether TRAP is associated with plasma level of TH17-, TH1-, and TH2-related cytokines in children with and without asthma, a cross-sectional study of 577 children (ages 6-14 years) with (n = 294) and without (n = 283) asthma in San Juan (Puerto Rico) was performed. Residential distance to a major road was estimated using geocoded home addresses for study participants. A panel of 14 cytokines, enriched for the TH17 pathway, was measured in plasma...
September 1, 2016: Pediatric Allergy, Immunology, and Pulmonology
keyword
keyword
85649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"